(Recombinant human erythropoietins)

Indications: correction of anemia associated with end- stage renal disease in patients maintained on haemodialysis; anemia in adults receiving platinum- containing cancer chemotherapy.

Cautions: same as Darbepoetin alpha

ContraIndications: same as Darbepoetin alpha

Side Effects: same as Darbepoetin alpha

Dose: in hemodialysis patients, initially by IV injection, 50 units/kg three times per week increased by 25 u/kg at intervals of 4 weeks according to response.

Max. dose, 200 u/kg three times a week.

If hemoglobin level increased at a rate exceeding 2 g/dL/month at 50 u/kg three times a week, a reduction of the dose is done by omitting one of the weekly doses.